Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic ... timing and achievement of clinical and ...

passed away at the age of 86. His life story was remarkable, rising from humble beginnings to shaping Malaysia’s economic and ...

The brightly colored "CoComelon" cartoons have become must-watch videos for babies and toddlers. But they've also raised ...

Please turn to Slide 4. Joining me today is John Jacobs ... For the Sanofi flu COVID-19 program, there are two milestones ...

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one <a target=_blank href= ...

XOLREMDI (mavorixafor) is a selective CXCR4 receptor antagonist approved in the U.S. for use in patients 12 years of age and older with WHIM syndrome ... as well as our research and development ...

Neil McFarlane, Zevra's President and Chief Executive Officer; LaDuane Clifton, our Chief Financial Officer; and Josh Schafer, our Chief Commercial Officer and EVP of Business Development ... review ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...

“We continue to take a balanced approach to building a portfolio of sustainable cashflow streams by selectively acquiring royalty economics across the lifecycle of drug development ... pediatric ...

Greetings, and welcome to Energy Vault's Third Quarter 2024 Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. It is now my pleasure to introduce to you ...

"In the third quarter and recent weeks Cognition Therapeutics achieved one of the most important milestones in its history as ... into the second quarter of 2025. Research and development expenses ...